Journals / Journal of Contemporary Medicine / 2023 / Cilt: 13 Sayı: 5

Evaluation of Hematological Biomarkers in Childhood Metabolic Dysfunction Associated Steatotic Liver Disease

Çocukluk Çağı Metabolik Disfonksiyonla İlişkili Steatotik Karaciğer Hastalığında Hematolojik Biyobelirteçlerin Değerlendirilmesi

Pages
1024–1032
Publication Date
2023-09-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion:Our study suggests that the presence of MASLD should be investigated in individuals, and possible complications can be prevented with early diagnosis and treatment approaches.As a result, we think that the use of hematological biomarkers will be useful for the simple and rapid detection of patients with suspected MASLD and who need further examination and treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim:We aimed to investigate the clinical significance and diagnostic value of inflammation-based biomarkers in children with a diagnosis of Metabolic Dysfunction Associated Steatotic Liver Disease(MASLD).
📊
Key Findings & Data:Methods:This study was carried out by retrospectively evaluating the files of patients followed up in the Department of Pediatric Hepatology at xxUniversity between July 2022 and January 2023.The study was completed with 120 patients with MASLD diagnosed according to the criteria of the AASLD and EASL, 80 healthy controls.Comparisons were made by calculating laboratory values and formulas through them.
💡
Conclusion & Impact:Conclusion:Our study suggests that the presence of MASLD should be investigated in individuals, and possible complications can be prevented with early diagnosis and treatment approaches.As a result, we think that the use of hematological biomarkers will be useful for the simple and rapid detection of patients with suspected MASLD and who need further examination and treatment.
🔬Design:Research Article
📍Scope:2022 Verileri
⚙️Variables:metabolik disfonksiyonla ilişkili steatotik karaciğer hastalığı · çocukluk çağı · biobelirteç

Abstract

Aim:We aimed to investigate the clinical significance and diagnostic value of inflammation-based biomarkers in children with a diagnosis of Metabolic Dysfunction Associated Steatotic Liver Disease(MASLD). Methods:This study was carried out by retrospectively evaluating the files of patients followed up in the Department of Pediatric Hepatology at xxUniversity between July 2022 and January 2023.The study was completed with 120 patients with MASLD diagnosed according to the criteria of the AASLD and EASL, 80 healthy controls.Comparisons were made by calculating laboratory values and formulas through them. Results:There were 50(41.7%)girls and 70(58.3%)boys in the patient group,and 40 girls (50.0%) and 40 boys(50.0%) in the control group.While 80 patients with Grade 0 detected in liver ultrasonography were taken as the control group;102(85%) Grade 1 and 18(15%)Grade 2-3 patients were considered as the patient group.The values of the patients were compared with the values of healthy volunteers.When the WBC, neutrophil, lymphocyte, platelet, MHR, RPR, RLR, MPR, WMR, GPR, SII and FIB-4score values were compared according to liver grading, a correlation was found in the tests performed on the patients. Conclusion:Our study suggests that the presence of MASLD should be investigated in individuals, and possible complications can be prevented with early diagnosis and treatment approaches.As a result, we think that the use of hematological biomarkers will be useful for the simple and rapid detection of patients with suspected MASLD and who need further examination and treatment.

Özet

Amaç: Çalışmamızda Metabolik Disfonksiyonla İlişkili Steatotik Karaciğer Hastalığı (MASLD) tanılı çocuklarda inflamasyon temelli biyobelirteçlerin klinik önemi ve tanısal değerini araştırmayı amaçladık. Yöntemler: Bu Çalışma, Temmuz 2022-Ocak 2023 tarihleri arasında xxÜniversitesi Çocuk Gastroenteroloji bölümünde takip edilen hasta dosyalarının retrospektif olarak değerlendirilmesi ile gerçekleştirilmiştir.AASLD ve EASL kriterlerine göre tanı konulan 120 MASL hastası ve 80 sağlıklı kontrol grubu ile çalışma tamamlanmıştır.Laboratuvar değerleri ve bunlar aracılığı ile formüller hesaplanarak karşılaştırmalar yapılmıştır. Bulgular: Hasta grubunda 50(%41.7) kız, 70(%58.3) erkek ve kontrol grubunda ise 40 kız (%50.0), 40 erkek(%50.0) idi.Karaciğer Ultrasonografilerinde Grade 0 tespit edilen 80 hasta kontrol grubu;102’si(%85)Grade 1 ve 18’i(%15)Grade 2-3 hasta grubu olarak kabul edildi. Hastaların değerleri, sağlıklı gönüllülerin değerleri ile karşılaştırıldı.Yapılan testlerde hastalarda WBC, nötrofil, lenfosit, platelet, MHO, RPO, RLO, MPO, WMO, GPO, Sİİ ve FIB-4 skor değerleri karaciğer Gradelendirilmesine göre karşılaştırıldığında korelasyon tespit edildi. Sonuç: MASLD’ın erken tespiti için etkili bir izleme göstergesine acilen ihtiyaç duyulmaktadır.Yapmış olduğumuz bu çalışma, kişilerde MASL varlığının araştırılması gerektiğini, erken tanı ve tedavi yaklaşımları ile olası komplikasyonların önüne geçilebileceğini düşündürmektedir.Sonuç olarak MASLD’den şüphelenilen, ileri tetkik ve tedaviye ihtiyaç duyan hastaların basit ve hızlı bir şekilde tespiti için hematolojik biyobelirteçlerin kullanımı faydalı olacağı düşüncesindeyiz.

🔖

Cite This Article

GÜMÜŞ, M., YORULMAZ, A., CANDAN, H., ÖZTÜRK, M., BUĞRUL, F., EMİROĞLU, H. H. (2023). Evaluation of Hematological Biomarkers in Childhood Metabolic Dysfunction Associated Steatotic Liver Disease. Journal of Contemporary Medicine, Cilt: 13 Sayı: 5, 1024–1032. https://ajindex.com/articles/964453

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Ludwig, J., et al., Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc, 1980. 55(7): 434-8. 2-Eslam, M., et al., MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 2020. 158(7): 1999-2014 e1. 3- Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2023 20:101133. doi: 10.1016/j.aohep.2023.101133. 4-Shah J, Okubote T, Alkhouri N. Overview of Updated Practice Guidelines for Pediatric Nonalcoholic Fatty Liver Disease. Gastroenterol Hepatol (N Y) 2018
  2. 407–14. 5-Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018
  3. 328–57. 6-Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A. The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis. PLoS One 2015
  4. e0140908. 7-Shaunak M, Byrne CD, Davis N, Afolabi P, Faust SN, Davies JH. Nonalcoholic fatty liver disease and childhood obesity. Arch Dis Child. 2021
  5. 3– 8. 8-Gokce S, Atbinici Z, Aycan Z, Çınar HG, Zorlu P. The relationship between pediatric non-alchololic fatty liver disease and cardiovasculer risk factors and increased risk of atherosclerosşs in obese children. Pediatr Cardiol 2013
  6. 308–15. 9-Akcam M, Boyaci A, Pirgon O, Koroglu M, Dundar BN. Importance of the liver ultrasound scores in pubertal obese children with nonalcoholic fatty liver disease. Clin Imaging 2013
  7. 504–8 10- Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021
  8. 2212–24. 11- Türkiye Karaciğer Araştırmaları Derneği. Alkol dışı yağlı karaciğer hastalığı (NAFLD) klinik rehberi. Ankara
  9. s. 11-51. 12-Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010
  10. 595–602. 13- Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 2018
  11. 908–922. 14-Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol 2018
  12. 15(6):349–64. 15-Qin B, Ma N, Tang Q, Wei T, Yang M, Fu H, et al. Neut